Education
About Us
Working with TipRanks
Follow Us
Shattuck Labs (STTK)
NASDAQ:STTK
STTK Stock Chart & Stats
$1.81
>-$0.01(-0.39%)
At close: 4:00 PM EST
$1.81
>-$0.01(-0.39%)
Day’s Range― - ―
52-Week Range$0.69 - $2.71
Previous CloseN/A
Volume43.14K
Average Volume (3M)550.09K
Market Cap
$114.30M
Enterprise Value-$7.11M
Total Cash (Recent Filing)$50.47M
Total Debt (Recent Filing)$2.02M
Price to Earnings (P/E)―
Beta2.99
Next Earnings
Nov 11, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding63,151,790
10 Day Avg. Volume553,172
30 Day Avg. Volume550,087
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.06
Enterprise Value/Revenue-0.19
Enterprise Value/Gross Profit-0.48
Enterprise Value/Ebitda0.11
Forecast
1Y Price Target
$2.67Price Target Upside47.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentSTTK is expected to transition to a clinical-stage company, which should support new interest in its first-in-class DR3 approach in inflammatory bowel disease.
Financial PositionThe company announced a financing that extends its cash runway into 2029, providing a strong financial foundation.
Regulatory ApprovalThe IND application for SL-325 has been cleared by the FDA, allowing for a Phase 1 clinical study to commence.
Bears Say
Analyst RatingAnalyst maintains a Hold Rating given the early stage of the company.
Financial PerformanceThe company reported a Q2 net loss of $12.5MM.
Shattuck Labs News
STTK FAQ
What was Shattuck Labs’s price range in the past 12 months?
Shattuck Labs lowest stock price was $0.69 and its highest was $2.71 in the past 12 months.
What is Shattuck Labs’s market cap?
Shattuck Labs’s market cap is $114.30M.
When is Shattuck Labs’s upcoming earnings report date?
Shattuck Labs’s upcoming earnings report date is Nov 11, 2025 which is in 18 days.
How were Shattuck Labs’s earnings last quarter?
Shattuck Labs released its earnings results on Aug 14, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.245 by $0.005.
Is Shattuck Labs overvalued?
According to Wall Street analysts Shattuck Labs’s price is currently Undervalued.
Does Shattuck Labs pay dividends?
Shattuck Labs does not currently pay dividends.
What is Shattuck Labs’s EPS estimate?
Shattuck Labs’s EPS estimate is -0.15.
How many shares outstanding does Shattuck Labs have?
Shattuck Labs has 63,151,790 shares outstanding.
What happened to Shattuck Labs’s price movement after its last earnings report?
Shattuck Labs reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.245. Following the earnings report the stock price went up 6.173%.
Which hedge fund is a major shareholder of Shattuck Labs?
Currently, no hedge funds are holding shares in STTK
Shattuck Labs Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.67 (47.51% Upside)
$2.67 (47.51% Upside)
Insider Transactions
Bought Shares
Worth $10.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.2%
Last 30 Days ▲ 12.3%
Last 30 Days ▲ 12.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.15%
12-Months-Change
Fundamentals
Return on Equity
-73.39%
Trailing 12-Months
Asset Growth
-49.95%
Trailing 12-Months
Company Description
Shattuck Labs
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
STTK Stock 12 Month Forecast
Average Price Target
$2.67
▲(47.51% Upside)
Technical Analysis
PolyPid
―
Coeptis Therapeutics Holdings
―
LAVA Therapeutics
―
Xilio Therapeutics
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
16.49% Insiders
4.44% Mutual Funds
0.19% Other Institutional Investors
76.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---